Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/06/008791
CTRI/2017/06/008791
Completed
Phase 2

An open label, multi-center, prospective clinical study to Evaluation of Efficacy and Safety of JPF-16 Capsules in Sexual Dysfunction in Females - NI

Chatarubhuj Pharmaceutical Co0 sites30 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: null- Female Sexual Dysfunction

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Health Condition 1: null- Female Sexual Dysfunction
Sponsor
Chatarubhuj Pharmaceutical Co
Enrollment
30
Status
Completed
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Chatarubhuj Pharmaceutical Co

Eligibility Criteria

Inclusion Criteria

  • •1\. Diagnosis of Female Sexual Interest/Arousal Disorder according to the DSM\-5 criteria (2013\)
  • •2\. Be involved in a stable relationship and have a partner
  • •3\. Healthy according to normal results of medical history, physical examination, laboratory values, and vital signs; exceptions may be made if the investigator considers an abnormality to be clinically irrelevant

Exclusion Criteria

  • •1\.Subjects with major illnesses and sexual dysfunction due to anatomical, surgical or pharmacological causes
  • •2\.Subjects with history of major psychiatric disorder
  • •3\.Subjects with history of central nervous system disorders such as stroke, transient ischemic attacks or spinal cord injury or pelvic surgery
  • •4\.Subjects with hypotension or uncontrolled hypertension, uncontrolled diabetes, hepatic impairment, renal impairment or hematological disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Phase 2
Clinical study on Ayuvita Forte Capsule in irregular periods with cysts in ovary.
CTRI/2019/11/022183Welex Laboratories Pvt Ltd25
Recruiting
Phase 4
A study to assess the safety and efficacy of fixed dose combination of Montelukast 10 mg plus Acebrophylline SR 200 mg tablet in patients having bronchial asthma
CTRI/2020/02/023237Sun Pharma Laboratories Limited
Completed
Not Applicable
A clinical trial to test the safety and effectiveness of Neuralzhein in management of memory loss related to age.Health Condition 1: F54- Psychological and behavioral factors associated with disorders or diseases classified elsewhere
CTRI/2019/08/020711exxus Laboratories DBA OPUS PHARMA
Completed
Phase 3
To evaluate safety and performance of CREDENCEâ?¢ BtK Sirolimus Eluting BioResorbable Peripheral Scaffold System in subjects with Critical Limb Ischemiafollowing Percutaneous Transluminal Angioplasty of below the knee arteries.Health Condition 1: I739- Peripheral vascular disease, unspecified
CTRI/2016/11/007473Meril Life Sciences Pvt Ltd30
Completed
Phase 3
Clinical trial to assess the safety and the efficacy of a new intravenous immune globulin (IGIV3I Grifols10%) in patients with idiopathic (immune) thrombocytopenic purpura.Health Condition 1: null- Chronic idiopathic (immune) thrombocytopenic purpuraHealth Condition 2: D693- Immune thrombocytopenic purpuraHealth Condition 3: D693- Immune thrombocytopenic purpura
CTRI/2009/091/000860Spectrum Clinical Research Pvt Ltd75